Your browser is no longer supported. Please, upgrade your browser.
RARE Ultragenyx Pharmaceutical Inc. daily Stock Chart
Ultragenyx Pharmaceutical Inc.
Index- P/E- EPS (ttm)-5.22 Insider Own1.90% Shs Outstand60.00M Perf Week8.55%
Market Cap5.12B Forward P/E- EPS next Y-4.06 Insider Trans-10.53% Shs Float56.97M Perf Month-3.54%
Income-300.50M PEG- EPS next Q-1.28 Inst Own- Short Float14.07% Perf Quarter32.89%
Sales159.40M P/S32.14 EPS this Y-79.30% Inst Trans3.09% Short Ratio15.75 Perf Half Y41.26%
Book/sh11.59 P/B7.32 EPS next Y7.90% ROA-26.30% Target Price85.50 Perf Year37.64%
Cash/sh13.47 P/C6.30 EPS next 5Y17.20% ROE-44.80% 52W Range31.99 - 91.77 Perf YTD98.64%
Dividend- P/FCF- EPS past 5Y-25.90% ROI-65.40% 52W High-7.55% Beta2.25
Dividend %- Quick Ratio4.10 Sales past 5Y- Gross Margin96.20% 52W Low165.21% ATR4.10
Employees740 Current Ratio4.10 Sales Q/Q156.00% Oper. Margin- RSI (14)57.21 Volatility4.18% 4.89%
OptionableYes Debt/Eq0.00 EPS Q/Q124.00% Profit Margin- Rel Volume0.57 Prev Close84.56
ShortableYes LT Debt/Eq0.00 EarningsJul 30 AMC Payout- Avg Volume509.13K Price84.84
Recom1.90 SMA203.05% SMA508.53% SMA20046.84% Volume289,732 Change0.33%
Aug-02-19Resumed Wedbush Outperform $75
Mar-27-19Upgrade Morgan Stanley Equal-Weight → Overweight $68 → $83
Feb-22-19Resumed Raymond James Outperform $80
Jan-02-19Downgrade Raymond James Outperform → Mkt Perform
Nov-08-18Upgrade Citigroup Sell → Neutral
Sep-10-18Initiated Morgan Stanley Equal-Weight $92
Jun-21-18Downgrade Credit Suisse Outperform → Neutral
May-11-18Upgrade Barclays Equal Weight → Overweight $62 → $74
May-10-18Initiated Goldman Neutral $63
Apr-18-18Upgrade SunTrust Hold → Buy
Mar-22-18Resumed Piper Jaffray Overweight $67
Feb-21-18Reiterated Stifel Buy $85 → $74
Jan-22-18Upgrade Evercore ISI In-line → Outperform
Jan-18-18Initiated Credit Suisse Outperform $67
Dec-05-17Reiterated Barclays Equal Weight $60 → $62
Dec-04-17Upgrade Jefferies Hold → Buy
Sep-14-17Upgrade Wedbush Neutral → Outperform $62
Aug-23-17Downgrade SunTrust Buy → Hold $55
Aug-17-17Initiated Evercore ISI In-line $63
Aug-08-17Reiterated H.C. Wainwright Neutral $72 → $75
Aug-04-20 08:31AM  
Jul-31-20 01:31PM  
Jul-30-20 07:00PM  
Jul-24-20 08:35AM  
Jul-22-20 08:35AM  
Jul-02-20 08:41AM  
Jul-01-20 12:11PM  
Jun-30-20 03:01PM  
Jun-23-20 12:20PM  
Jun-19-20 01:16PM  
Jun-18-20 01:16PM  
Jun-11-20 10:21AM  
Jun-05-20 11:31AM  
May-28-20 08:30AM  
May-21-20 08:30AM  
May-15-20 08:00AM  
May-13-20 04:01PM  
May-11-20 04:02PM  
May-07-20 07:13PM  
May-06-20 06:35PM  
May-04-20 08:30AM  
Apr-30-20 04:05PM  
Apr-28-20 06:28PM  
Apr-27-20 12:32PM  
Apr-01-20 09:37AM  
Mar-31-20 08:00PM  
Mar-29-20 12:12PM  
Mar-21-20 10:39AM  
Mar-16-20 08:30AM  
Mar-14-20 11:30AM  
Mar-09-20 05:10PM  
Mar-03-20 04:15PM  
Feb-27-20 08:00AM  
Feb-21-20 08:30AM  
Feb-18-20 11:20PM  
Feb-14-20 09:18AM  
Feb-13-20 04:01PM  
Feb-06-20 04:01PM  
Feb-05-20 05:19AM  
Jan-16-20 07:22AM  
Jan-15-20 04:01PM  
Jan-14-20 08:53AM  
Jan-13-20 10:14AM  
Jan-10-20 07:13AM  
Jan-09-20 04:01PM  
Dec-29-19 09:40PM  
Dec-19-19 08:30AM  
Dec-18-19 08:30AM  
Dec-10-19 09:11PM  
Dec-05-19 04:32PM  
Dec-03-19 10:15AM  
Nov-26-19 08:30AM  
Nov-09-19 10:43AM  
Nov-08-19 10:02AM  
Nov-06-19 11:00AM  
Nov-05-19 05:35PM  
Oct-30-19 08:30AM  
Oct-28-19 10:32AM  
Oct-26-19 02:55PM  
Oct-18-19 10:23AM  
Oct-15-19 10:57AM  
Oct-14-19 08:30AM  
Oct-02-19 08:31AM  
Sep-30-19 08:30AM  
Sep-11-19 03:15PM  
Sep-10-19 09:00AM  
Sep-04-19 09:42AM  
Sep-03-19 12:38PM  
Aug-31-19 09:32AM  
Aug-30-19 08:30AM  
Aug-23-19 07:36AM  
Aug-15-19 04:35PM  
Aug-14-19 08:30AM  
Aug-13-19 08:30AM  
Aug-12-19 10:59AM  
Aug-10-19 11:18AM  
Aug-02-19 10:28AM  
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia; and Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII. The company is also developing small-molecule pipeline comprising UX007, a synthetic triglyceride for the treatment of long chain fatty-acid oxidation disorders, which is a set of rare metabolic diseases that prevents the conversion of fat into energy; and gene therapy pipeline consisting of DTX301, an adeno-associated virus 8 gene therapy product candidate for the treatment of patients with ornithine transcarbamylase, as well as DTX401, an AAV8 gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia. In addition, the company is developing UX068, which is in preclinical development for the treatment of creatine transporter deficiency (CTD); and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Arcturus Therapeutics Holdings Inc. to develop additional nucleic acid therapies for rare diseases. Ultragenyx Pharmaceutical Inc. was founded in 2010 and is headquartered in Novato, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KAKKIS EMIL DPresident & CEOJul 13Sale85.3540,0003,414,0002,419,741Jul 15 01:22 PM
Huizenga Theodore AlanSVP, Controller and PAOJul 08Option Exercise21.002,00042,00018,582Jul 10 05:21 PM
Huizenga Theodore AlanSVP, Controller and PAOJul 08Sale91.002,638240,05816,582Jul 10 05:21 PM
Fust Matthew KDirectorJul 06Option Exercise21.006,181129,80119,731Jul 08 12:30 PM
Fust Matthew KDirectorJul 06Sale90.006,181556,29013,550Jul 08 12:30 PM
Huizenga Theodore AlanSVP, Controller and PAOJul 01Option Exercise21.001,50031,50018,720Jul 06 02:21 PM
Fust Matthew KDirectorJul 01Option Exercise21.005,000105,00018,550Jul 06 02:21 PM
Huizenga Theodore AlanSVP, Controller and PAOJul 01Sale81.002,611211,49117,220Jul 06 02:21 PM
Fust Matthew KDirectorJul 01Sale85.005,000425,00013,550Jul 06 02:21 PM
Sharp ShaliniCFO & Executive Vice PresidentJun 04Option Exercise48.432,564124,175103,772Jun 05 04:59 PM
Sharp ShaliniCFO & Executive Vice PresidentJun 04Sale74.012,564189,762101,208Jun 05 04:59 PM
Sharp ShaliniCFO & Executive Vice PresidentJun 03Option Exercise48.4310,234495,633111,442Jun 05 04:59 PM
Sharp ShaliniCFO & Executive Vice PresidentJun 03Sale74.2310,234759,670101,208Jun 05 04:59 PM
Huizenga Theodore AlanSVP, Controller and PAOMay 26Sale74.9326019,48218,331May 27 03:14 PM
Sharp ShaliniCFO & Executive Vice PresidentMay 19Option Exercise60.577,128431,710104,851May 20 07:49 PM
Sharp ShaliniCFO & Executive Vice PresidentMay 19Sale73.327,128522,625100,944May 20 07:49 PM
Aliski WilliamDirectorMay 18Option Exercise40.377,500302,77555,424May 20 07:50 PM
Sharp ShaliniCFO & Executive Vice PresidentMay 18Option Exercise70.5719,5931,382,678122,929May 20 07:49 PM
Aliski WilliamDirectorMay 18Sale74.657,500559,87547,924May 20 07:50 PM
Sharp ShaliniCFO & Executive Vice PresidentMay 18Sale73.3321,9851,612,260100,944May 20 07:49 PM
Aliski WilliamDirectorMay 18Sale74.0220,0001,480,32270,350Jun 03 04:26 PM
Fust Matthew KDirectorMay 18Sale75.001,875140,62511,000May 19 07:13 PM
Parschauer Karah HerdmanEVP and General CounselMay 18Sale74.722,722203,37427,312May 19 07:12 PM
Huizenga Theodore AlanSVP, Controller and PAOMay 15Option Exercise21.001,50031,50020,219May 19 07:15 PM
Huizenga Theodore AlanSVP, Controller and PAOMay 15Sale71.002,461174,73118,719May 19 07:15 PM
Fust Matthew KDirectorApr 22Sale65.001,875121,87512,875Apr 24 01:00 PM
Huizenga Theodore AlanSVP, Controller and PAOJan 14Sale61.001,00061,00015,946Jan 15 01:08 PM
Sharp ShaliniCFO & Executive Vice PresidentSep 16Option Exercise5.5431,843176,31799,089Sep 17 07:25 PM
KAKKIS EMIL DPresident & CEOSep 11Buy43.635,000218,150472,479Sep 11 12:35 PM